- Home
- ATRA vs PLX Comparison
ATRA vs PLX Comparison
Compare ATRA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATRA | PLX |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.4M | 142.3M |
| IPO Year | 2014 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ATRA | PLX |
|---|---|---|
| Price | $4.55 | $2.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.00 | ★ $12.00 |
| AVG Volume (30 Days) | 610.3K | ★ 836.6K |
| Earning Date | 03-06-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.97 | 0.07 |
| Revenue | ★ $151,930,000.00 | $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $16.65 |
| P/E Ratio | ★ $2.31 | $29.53 |
| Revenue Growth | ★ 51.27 | 35.41 |
| 52 Week Low | $4.25 | $1.32 |
| 52 Week High | $19.15 | $3.10 |
Technical Indicators
Market Signals| Indicator | ATRA | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 23.81 | 62.24 |
| Support Level | $4.25 | $1.97 |
| Resistance Level | $5.19 | $2.11 |
| Average True Range (ATR) | 1.63 | 0.10 |
| MACD | -1.54 | 0.03 |
| Stochastic Oscillator | 2.07 | 80.72 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.